secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0001171843-24-006945
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech FY2024 net loss $6.2M ($1.93/sh); cash $1.0M, negative working capital
--------------------------------------------------------------------------------

- Net loss $6.2M ($1.93/sh) vs $8.4M ($2.93/sh) prior year; operating expenses down 24% to $7.0M.
- Cash and equivalents $1.0M at Sep 30; negative working capital of $0.2M.
- Post-year end: $1.5M from CEO-affiliated entity + $0.6M net from ATM offering.
- Pivoted EB05 (paridiprubart) to U.S. govt-funded ARDS study; plans EB06 IND submission.
- Topline Phase 2 EB06 results expected 12-18 months after FDA clearance; funded subject to capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184324006945/0001171843-24-006945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184324006945/f8k_121324.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer